There’s a lot to digest in the October 30 White House’s AI Executive Order. Our tracker is a useful starting point to identify key provisions and monitor the government’s progress against specific milestones, but grappling with the substance is an entirely different matter. This blog post, focusing on Section 4 of the EO (“Developing Guidelines, Standards, and Best Practices for AI Safety and Security”), is the first in a series that summarizes interesting provisions, shares some of our initial reactions, and highlights some of CSET’s research that may help the USG tackle the EO.

The August 9 Executive Order aims to restrict certain U.S. investments in key technology areas. In a previous post, we proposed an end-user approach to crafting an AI investment prohibition. In this follow-on post, we rely on existing and hypothetical transactions to test scenarios where U.S. investments in China’s AI ecosystem would or would not be covered under the proposed program, and highlight outstanding challenges.

The EU AI Act is nearing formal adoption and implementation. Read this blog post, with updated analysis following the December 2023 political agreement, by CSET’s resident EU expert and Research Fellow, Mia Hoffmann. Learn what we know about the Act and what it means for AI regulation in the EU (and the world).

The Replicator effort by the U.S. Department of Defense (DoD) is intended to overcome some of the military challenges posed by China’s People’s Liberation Army (PLA). This blog post intends to both identify tradeoffs for the Department to consider as it charts the path for Replicator, and to provide a sense for the state of industry readiness to support.

Drawing from prior CSET research, this blog post describes different domestic and international initiatives the Chinese government and companies are pursuing to shore up investment in AI and meet China’s strategic objectives, as well as indicators to track their future trajectories.

Steph Batalis, Caroline Schuerger and Vikram Venkatram explore three notable areas in the life sciences where LLMs are catalyzing meaningful advances: drug discovery, genetics, and precision medicine.